[go: up one dir, main page]

BE2013C055I2 - - Google Patents

Download PDF

Info

Publication number
BE2013C055I2
BE2013C055I2 BE2013C055C BE2013C055C BE2013C055I2 BE 2013C055 I2 BE2013C055 I2 BE 2013C055I2 BE 2013C055 C BE2013C055 C BE 2013C055C BE 2013C055 C BE2013C055 C BE 2013C055C BE 2013C055 I2 BE2013C055 I2 BE 2013C055I2
Authority
BE
Belgium
Prior art keywords
eye
reduce
vitreous
plasmin
disorder
Prior art date
Application number
BE2013C055C
Other languages
English (en)
Original Assignee
Oxurion NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9949140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2013C055(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxurion NV filed Critical Oxurion NV
Publication of BE2013C055I2 publication Critical patent/BE2013C055I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02005—Chondroitin AC lyase (4.2.2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02019—Chondroitin B lyase (4.2.2.19)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Insulating Materials (AREA)
BE2013C055C 2002-12-06 2013-08-29 BE2013C055I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0228409.9A GB0228409D0 (en) 2002-12-06 2002-12-06 Pharmacological vitreolysis

Publications (1)

Publication Number Publication Date
BE2013C055I2 true BE2013C055I2 (fr) 2023-03-07

Family

ID=9949140

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2013C055C BE2013C055I2 (fr) 2002-12-06 2013-08-29

Country Status (24)

Country Link
US (11) US7547435B2 (fr)
EP (3) EP2327416B1 (fr)
JP (4) JP5426063B2 (fr)
CN (1) CN100577202C (fr)
AT (1) ATE534400T1 (fr)
AU (1) AU2003300821C1 (fr)
BE (1) BE2013C055I2 (fr)
BR (2) BRPI0310144A8 (fr)
CA (1) CA2508606C (fr)
CY (2) CY1112561T1 (fr)
DK (1) DK1581254T3 (fr)
ES (2) ES2377965T3 (fr)
FR (1) FR13C0052I2 (fr)
GB (1) GB0228409D0 (fr)
HU (1) HUS1300040I1 (fr)
IL (3) IL169008A (fr)
LU (1) LU92273I2 (fr)
MX (1) MXPA05006038A (fr)
NO (4) NO333837B1 (fr)
NZ (1) NZ541075A (fr)
PT (2) PT2327416T (fr)
SI (1) SI1581254T1 (fr)
WO (1) WO2004052228A2 (fr)
ZA (1) ZA200505193B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7152975B2 (en) * 2000-11-10 2006-12-26 Cooper Vision, Inc. Junctionless ophthalmic lenses and methods for making same
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
DK1740698T3 (da) 2004-04-22 2010-10-25 Talecris Biotherapeutics Inc Rekombinant modificeret plasmin
JP4796787B2 (ja) * 2005-04-28 2011-10-19 富士フイルム株式会社 ラビリンチュラ類への遺伝子導入法
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
WO2007005856A1 (fr) * 2005-06-30 2007-01-11 Ista Pharmaceuticals, Inc. Utilisation de l'hyaluronidase en combinaison ave la plasmine pour l'induction du decollement posterieur du vitre
WO2007047874A2 (fr) * 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Plasmine modifiée par recombinaison
US20070134230A1 (en) * 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes
US20070134231A1 (en) * 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes and compositions thereof
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
US20070212358A1 (en) * 2006-03-10 2007-09-13 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
CN101437543A (zh) * 2006-05-04 2009-05-20 佛维雅制药股份有限公司 用于治疗新生血管病的包含vegf抑制剂和丝氨酸蛋白酶的组合
HUE024916T2 (en) * 2007-11-29 2016-02-29 Grifols Therapeutics Inc Recombinantly modified plasmin
EP2249863A4 (fr) * 2008-01-22 2011-12-28 Omnio Healer Ab Méthode d'amélioration de la cicatrisation des plaies
AU2009231396B2 (en) * 2008-03-31 2015-05-07 Scarcell Therapeutics Method for the cosmetic treatment of skin ageing
KR20160110544A (ko) 2008-06-04 2016-09-21 그리폴스 테라퓨틱스 인코포레이티드 플라스민의 제조를 위한 조성물, 방법 및 키트
PL2403865T3 (pl) 2009-03-03 2016-01-29 Grifols Therapeutics Inc Sposoby wytwarzania plazminogenu
US8858924B2 (en) 2009-03-26 2014-10-14 Warsaw Orthopedic, Inc. Compositions and methods for treatment of hemorrhage
US9226953B2 (en) 2009-07-10 2016-01-05 Thrombogenics Nv Variants of plasminogen and plasmin
US20120189609A1 (en) 2009-08-28 2012-07-26 Thrombogenics Nv Improvement to trabeculectomy
US20110135626A1 (en) * 2009-12-08 2011-06-09 Alcon Research, Ltd. Localized Chemical Lysis of Ocular Tissue
RU2435553C1 (ru) * 2010-03-10 2011-12-10 Арсений Александрович Кожухов Способ лечения центральных субретинальных кровоизлияний
MX337248B (es) 2011-01-05 2016-02-19 Thrombogenics Nv Variantes de plasminogeno y plasmina.
US20120329873A1 (en) * 2011-06-17 2012-12-27 Li yong-xin D-serine for the treatment of visual system disorders
MX347808B (es) 2011-08-12 2017-05-15 Thrombogenics Nv Variantes de plasminogeno y plasmina.
RU2484795C2 (ru) * 2011-08-18 2013-06-20 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ индукции задней отслойки стекловидного тела с помощью миниплазмина
EP2785739B1 (fr) 2011-12-01 2017-03-15 ThromboGenics N.V. Amélioration du résultat de la trabéculectomie
CN103205410B (zh) * 2012-01-13 2018-03-06 蔺莹莹 重组微纤维蛋白溶酶及其制备方法和应用
KR20150005631A (ko) 2012-04-24 2015-01-14 쓰롬보제닉스 엔.브이. 항-pdgf-c 항체
US9730888B2 (en) 2013-03-14 2017-08-15 Wayne State University Method of enhancing delivery of therapeutic compounds to the eye
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US9459201B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
FR3034992A1 (fr) 2015-04-15 2016-10-21 Arcadophta Milieu plasmatique ex vivo autologue riche en plasmine et procede d'obtention
WO2017101867A1 (fr) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 Méthode de prévention ou de traitement de la neuropathie diabétique et des affections associées
US11090372B2 (en) 2015-12-18 2021-08-17 Talengen International Limited Method of treating diabetic nephropathy comprising administering plasminogen
WO2017101870A1 (fr) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 Procédé pour prévenir ou traiter la rétinopathie diabétique
EP3397276A4 (fr) 2015-12-30 2019-12-18 Kodiak Sciences Inc. Anticorps et conjugués de ceux-ci
RU2619991C1 (ru) * 2016-02-18 2017-05-22 Павел Владимирович Лыскин Способ лечения витреомакулярного тракционного синдрома
US20190031762A1 (en) 2016-03-10 2019-01-31 Thrombogenics Nv Posterior ocular fibrosis inhibition by antagonizing placental growth factor
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
JP7171572B2 (ja) 2016-12-15 2022-11-15 タレンゲン インターナショナル リミテッド 糖尿病を治療するための新しい方法
AU2018242882B2 (en) 2017-03-28 2021-08-12 Morinaga Milk Industry Co., Ltd. Novel Bifidobacterium genus bacterium
RU2674926C1 (ru) * 2018-02-01 2018-12-13 Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации (ФГАУ "НМИЦ "МНТК "Микрохирургия глаза" им. акад. С.Н. Способ оценки эффективности витреолизиса помутнений стекловидного тела
KR20200140817A (ko) 2018-03-02 2020-12-16 코디악 사이언시스 인코포레이티드 Il-6 항체 그리고 이의 융합 작제물 및 접합체
CN110361242B (zh) * 2019-08-14 2022-01-18 武汉赛维尔生物科技有限公司 一种用于眼球组织的固定液以及眼球组织制片的预处理方法
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN116716251A (zh) * 2023-06-20 2023-09-08 中国医学科学院北京协和医院 一种玻璃体样本的单细胞处理方法及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US658972A (en) * 1900-04-09 1900-10-02 Interchangeable Brake Beam Company Brake-beam.
US2624691A (en) * 1946-04-22 1953-01-06 Parke Davis & Co Fibrinolysin derived from blood and methods of obtaining the same
DK98833C (da) 1961-04-25 1964-05-25 Novo Terapeutisk Labor As Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger.
US3234106A (en) * 1962-12-03 1966-02-08 Cutter Lab Soluble, purified profibrinolysin and fibrinolysin and method of producing same
US3950513A (en) * 1965-12-03 1976-04-13 Novo Terapeutisk Laboratorium A/S Process of stabilizing therapeutically useful plasmin solutions
IT1194135B (it) * 1981-01-05 1988-09-14 Novo Industri As Composizioni di plasmina stabilizzata e metodo per la loro preparazione
GB8504025D0 (en) * 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
US4774087A (en) 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
US5288485A (en) * 1989-08-31 1994-02-22 Kao Corporation Vasodilating agent
ZA912770B (en) 1990-04-16 1992-01-29 Bethesda Eye Inst Enzymatic disinsertion of vitreous body
US5288489A (en) * 1991-08-28 1994-02-22 Orion Therapeutic Systems, Inc. Fibrinolysis and fibrinogenolysis treatment
AU4661493A (en) * 1992-07-01 1994-01-31 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
US5304118A (en) * 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
US6610292B2 (en) 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
US5866120A (en) * 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
US5973779A (en) 1996-03-29 1999-10-26 Ansari; Rafat R. Fiber-optic imaging probe
US6207066B1 (en) * 1996-07-23 2001-03-27 Nuvue Technologies, L.L.C. Method for purification of a blood component
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US5722428A (en) * 1996-10-29 1998-03-03 Washington University Method for producing a posterior vitreous detachment
US6596725B2 (en) * 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
AU7693698A (en) 1997-05-22 1998-12-11 Ista Pharmaceuticals, Inc Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
CN1322126C (zh) 1998-02-04 2007-06-20 思罗姆-X股份有限公司 免疫原性降低和/或清除率降低的葡激酶衍生物的鉴定、生产和应用
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6462071B1 (en) 2000-03-02 2002-10-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
US6733750B1 (en) * 1999-03-09 2004-05-11 Minu, L.L.C. Process and composition for inducing posterior vitreous detachment
US6899877B2 (en) * 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US20040081643A1 (en) * 1999-03-09 2004-04-29 Peyman Gholam A. Process for inhibiting vascular proliferation in the eye
US6585972B2 (en) * 1999-03-09 2003-07-01 Gholam A. Peyman Process for crosslinking of collagen in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
EP1229116A4 (fr) 1999-11-10 2003-01-22 Ct For Advanced Science & Tech Procede de preparation de fractions cellulaires contenant des hemangioblastes
US6964764B2 (en) * 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6355243B1 (en) * 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
DE60118186T2 (de) * 2000-05-12 2006-12-28 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
AU2002218890A1 (en) * 2000-12-21 2002-07-01 Thromb-X N.V. A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell
US20020139378A1 (en) * 2001-03-28 2002-10-03 Trese Michael T. Method for creating a separation of posterior cortical vitreous from the retina of the eye
FI20011132A0 (fi) 2001-05-30 2001-05-30 Innovationsagentur Markkeri hematopoieettisten kantasolujen tunnistamiseen
US7776026B2 (en) * 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
US6787135B2 (en) * 2002-03-13 2004-09-07 William Beaumont Hospital Modification of vitreal matrix metalloproteinase activity
WO2004045558A2 (fr) * 2002-11-18 2004-06-03 President And Fellows Of Harvard College Compositions et procedes pour traiter des troubles thrombotiques
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US20070212358A1 (en) * 2006-03-10 2007-09-13 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment

Also Published As

Publication number Publication date
JP5426063B2 (ja) 2014-02-26
EP2327416B1 (fr) 2019-05-01
EP2327415B1 (fr) 2017-10-18
US7803368B2 (en) 2010-09-28
BRPI0310144A8 (pt) 2018-04-24
US9770494B2 (en) 2017-09-26
HK1082419A1 (en) 2006-06-09
CN100577202C (zh) 2010-01-06
ZA200505193B (en) 2007-08-29
AU2003300821A1 (en) 2004-06-30
ES2731625T3 (es) 2019-11-18
IL213838A0 (en) 2011-07-31
WO2004052228A3 (fr) 2004-10-07
NO333837B1 (no) 2013-09-30
PT1581254E (pt) 2012-02-06
US20110171190A1 (en) 2011-07-14
US20090074739A1 (en) 2009-03-19
CA2508606C (fr) 2015-07-28
JP5451533B2 (ja) 2014-03-26
US20080050356A1 (en) 2008-02-28
CA2508606A1 (fr) 2004-06-24
IL202851A (en) 2015-04-30
JP2013241448A (ja) 2013-12-05
FR13C0052I1 (fr) 2013-04-10
NO343759B1 (no) 2019-06-03
BR0317033A (pt) 2005-10-25
JP5739487B2 (ja) 2015-06-24
MXPA05006038A (es) 2006-03-08
NO2013016I2 (no) 2017-06-28
WO2004052228A2 (fr) 2004-06-24
IL169008A (en) 2011-08-31
EP2327415A1 (fr) 2011-06-01
NO20121169A1 (no) 2012-10-12
JP2006518708A (ja) 2006-08-17
US8460655B2 (en) 2013-06-11
SI1581254T1 (sl) 2012-05-31
NO20121170A1 (no) 2012-10-12
US7914783B2 (en) 2011-03-29
GB0228409D0 (en) 2003-01-08
CY1112561T1 (el) 2015-11-04
LU92273I2 (fr) 2013-10-29
EP1581254A2 (fr) 2005-10-05
EP2327416A1 (fr) 2011-06-01
ES2377965T3 (es) 2012-04-03
NO2013016I1 (no) 2013-11-19
US20130302304A1 (en) 2013-11-14
EP1581254B1 (fr) 2011-11-23
US20080095753A1 (en) 2008-04-24
US20130195887A1 (en) 2013-08-01
US8834869B2 (en) 2014-09-16
US8383105B2 (en) 2013-02-26
CY2013033I2 (el) 2015-11-04
PT2327416T (pt) 2019-07-04
ATE534400T1 (de) 2011-12-15
AU2003300821B2 (en) 2009-07-09
US20050118158A1 (en) 2005-06-02
US20110300123A1 (en) 2011-12-08
EP1581254A4 (fr) 2007-03-28
JP5996026B2 (ja) 2016-09-21
JP2015131842A (ja) 2015-07-23
US9186394B2 (en) 2015-11-17
US20130202613A1 (en) 2013-08-08
LU92273I9 (fr) 2019-01-15
HUS1300040I1 (hu) 2013-08-15
NO20052988D0 (no) 2005-06-17
US20150064161A1 (en) 2015-03-05
US7867489B2 (en) 2011-01-11
AU2003300821C1 (en) 2012-03-22
JP2010222369A (ja) 2010-10-07
NZ541075A (en) 2008-02-29
FR13C0052I2 (fr) 2014-11-21
CN1738641A (zh) 2006-02-22
US7547435B2 (en) 2009-06-16
CY2013033I1 (el) 2015-11-04
IL202851A0 (en) 2011-07-31
US20090081187A1 (en) 2009-03-26
US8747842B2 (en) 2014-06-10
NO20052988L (no) 2005-09-05
DK1581254T3 (da) 2012-02-27

Similar Documents

Publication Publication Date Title
BE2013C055I2 (fr)
ATE426413T1 (de) Verfahren und zusammensetzungen zur behandlung von okularer neovaskularisierung und nervenverletzungen
MX351152B (es) Compstatina y analogos de la misma para tratar trastornos oculares.
ATE429914T1 (de) Verwendung von makroliden zur wiederherstellung der kornealempfindungen
DK1515741T3 (da) Anvendelse af kollagen-hydrolysat til viskositetssænkning af en sammensætning omfattende guargummi
WO2004069181A3 (fr) Compositions d'un agent modulateur de l'aquaporine et d'un agent modulateur de l'humeur aqueuse pour le traitement d'une pression intra-oculaire elevee
BR0317774A (pt) Uso de rimexolona no tratamento de olho seco
AR036199A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
ATE535257T1 (de) Ophthalmologische formulierung mit methylsulfonylmethan und ciprofloxacin
DK1263363T3 (da) Farvet viskoelastisk sammensætning
CY1106409T1 (el) Παραγωγα κινολινης
ATE550015T1 (de) Verfahren und zusammensetzung zur behandlung von rhinitis
MX2007010295A (es) Composiciones oftalmologicas novedosas y metodo para su uso.
Yoon et al. Recurrent herpes simplex keratitis after verteporfin photodynamic therapy for corneal neovascularization
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
WO2002036096A8 (fr) Produits viscoelastiques transitionnels ne necessitant pas d'aspiration destines a la chirurgie
RU2005104096A (ru) Способ лечения пролиферативной витреоретинопатии
UA39527A (uk) Спосіб лікування опіку очей